Protherics PLC, the biopharmaceutical company focused on critical care and oncology (the "Company"), received notification on 19 January 2006 from Aviva plc that, as at 18 January 2006, Aviva plc and its subsidiaries held a beneficial interest in 12,383,731 ordinary shares, representing 4.79% of the issued share capital of the Company, and a total interest in 27,603,457 ordinary shares, representing 10.68% of the issued share capital of the Company.
